Risk, BarryBalls explanation over on YMB seems to
Post# of 30028
Posted On: 07/17/2014 4:21:14 PM
Risk, BarryBalls explanation over on YMB seems to be shedding some light in the mist! " If they are presenting the data on July 31st, you won't know if the numbers are in the mid 90s until July 31st. Nobody here will be able to tell you that information. This is not meant to be an insult but you have over-analyzed this so much that you have mixed up all of the tests and data that has been presented. Now it's like you are trying to dig your way out of the hole you are in and you're just getting more confused. Read the post titled "Gerald explains" that was posted earlier. It hits on the key points. Again, I'm not trying to criticize you.
The "Future Work" section of the 7-year study poster says specifically that initial sens and spec data from the Bridge study will be presented on July 31st. That study involves 72 subjects and is designed to compare version 2 to version 1 in AD vs cognitively-intact patients. Even the raw data from Provista from the 7-year study showed 90% accuracy in AD vs cognitively-intact (see today's blog). The company believes a better-managed and designed study (i.e. the Bridge Study) will produce even better results. BD is running that study so we can expect it to be well-managed.
The key point from today's blog and from the 7-year study is that the company's view of the science seems to be valid. They believe the current study will show the accuracy needed to proceed to CLIA.
The 72 patient Steiler study was from 2001. It's just a coincidence that the Bridge Study also has 72. The 2012 Steiler study had 88 subjects. 72 (from 2001) and 88 (from 2012) equals 160. BD did the study. The title of the study is "Analytical Performance of the Lympro Assay." It's poster 1 from Monday and the study validated Steiler's work, which is a good thing. It's staring you right in the face and you are still looking for it".
Thank You BerryBalls 2003 over on YMB
The "Future Work" section of the 7-year study poster says specifically that initial sens and spec data from the Bridge study will be presented on July 31st. That study involves 72 subjects and is designed to compare version 2 to version 1 in AD vs cognitively-intact patients. Even the raw data from Provista from the 7-year study showed 90% accuracy in AD vs cognitively-intact (see today's blog). The company believes a better-managed and designed study (i.e. the Bridge Study) will produce even better results. BD is running that study so we can expect it to be well-managed.
The key point from today's blog and from the 7-year study is that the company's view of the science seems to be valid. They believe the current study will show the accuracy needed to proceed to CLIA.
The 72 patient Steiler study was from 2001. It's just a coincidence that the Bridge Study also has 72. The 2012 Steiler study had 88 subjects. 72 (from 2001) and 88 (from 2012) equals 160. BD did the study. The title of the study is "Analytical Performance of the Lympro Assay." It's poster 1 from Monday and the study validated Steiler's work, which is a good thing. It's staring you right in the face and you are still looking for it".
Thank You BerryBalls 2003 over on YMB
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼